Abstract |
Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus ( HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 ( prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non- nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus ( HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non- nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025.
|
Authors | Erik De Clercq |
Journal | Expert opinion on emerging drugs
(Expert Opin Emerg Drugs)
Vol. 13
Issue 3
Pg. 393-416
(Sep 2008)
ISSN: 1744-7623 [Electronic] England |
PMID | 18764719
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-HIV Agents
- Antiviral Agents
- HIV Protease Inhibitors
- Integrase Inhibitors
- Protease Inhibitors
- Reverse Transcriptase Inhibitors
|
Topics |
- Anti-HIV Agents
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- DNA Virus Infections
(drug therapy)
- HIV Protease Inhibitors
(therapeutic use)
- Hepatitis, Viral, Human
(drug therapy)
- Humans
- Integrase Inhibitors
(therapeutic use)
- Protease Inhibitors
(therapeutic use)
- RNA Virus Infections
(drug therapy)
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Virus Diseases
(drug therapy)
|